1. Market Research
  2. > Pharmaceutical Market Trends

Patient Assistance Programs: Payer and Pharma Perspectives

  • October 2014
  • Firstword Pharma
Report ID: 2405519

Summary

Table of Contents




Patient assistance programs (PAPs) are evolving in response to increasingly restrictive formularies and payer criticism. Patient Assistance Programs: Payer and Pharma Perspectives is a report that gives unique insight into payer attitudes and opinions on the future of PAPs.

As the numbers grow for Americans without private health insurance, the answer for many has been patient assistant programs. But as the pharmaceutical industry moved towards co-pay and coupon models, payers have been increasingly resistant and critical of the new PAP schemes.

FirstWord’s Patient Assistance Programs: Payer and Pharma Perspectives report offers an insightful and thorough examination of the current PAP environment, evaluating payer moods, attitudes and strategies.

Based on in-depth interviews with national payers and pharmaceutical industry experts, the report is an important tool for finding the optimal strategy and approach to the development and implementation of PAPs.







Key Takeaways

Gain insight into payer attitudes and strategies regarding the true cost of PAPs to the healthcare system
Learn which factors influence payer decision making when it comes to supporting PAPs and how that can be leveraged
Discover when pharma should engage with payers in the development and implementation of PAPS
Learn payer attitudes on a range of key issues, including the value of measuring PAP impact on patient adherence and health outcomes
Gain insight into how payers and industry experts predict PAPs will change in the future

Get Answers to Critical Questions

What factors would positively influence payer attitudes towards PAPs?
As formularies become more restrictive, what does the future hold for PAPs?
What do payers predict will happen with regards regulating PAPs?
What are the key drivers of distrust among payers over PAPs and how can this be reversed?
What can be done to increase data capture to improve quality of care?
What is the industry view of PAPs, and how does this compare with the views of payers?

Key Features

Insight into payer criticisms and opinions on issues such as PAPs as ‘backdoor’ route to market access, ensuring product uptake and a mechanism for maintaining high prices
Overview of different types of patient assistant programs across the US
Examination of the key drivers in PAP development and implementation
Key findings into the role of PAPs as essential mechanisms in maintaining competitiveness
Recommendations by payers to increase flexible and ongoing interaction with pharmaceutical companies

Expert Contributors

Pharmacy director, government health plan
Pharmacy director, national health insurer
Executive Vice President of a national Pharmacy Benefits Manager (PBM)
Chief Medical Officer, Managed Care Organisation
Health plan medical director
Medical director at global level for a major pharmaceutical company
Health Outcomes director at a US affiliate for a top pharmaceutical company

Key Quotes from Contributors
“Years ago, patient assistance program means programs that help out patients who were below a certain level on the poverty line, because they couldn't afford their medications. Now patient assistance program means I don't care what tier my drug is on, I'm going to give somebody a co-pay card so they can get my drug irrespective of how the payer is handling those drugs.”
Pharmacy Director, government health plan


“My goal if somebody needs an oral oncology drug is not to have them take $2,500 out of their bank accounts for them to get the drug. My argument with the manufacturer would be don't charge $100,000 for the drug and stop giving away $2,500 coupons.”
Chief Medical Officer

“It doesn't make me feel anything if they don't show a willingness to change the programme and work with me on something. If they just want to keep running the programme and ramming it down my throat, I feel pretty bad about that. If they want to work and look at a collaborative approach, it makes me feel a lot better.”
Executive Vice President PBM


“I think that these kinds of assistance programs, from the company's perspective, they realise are critical in terms of maintaining trust with the regulators and maintaining trust for the patient. They know that there has to be a fine balance between making sure people get access to the drugs, especially in countries which contributed the development of the drug.”
Global Medical Director, major pharmaceutical company.



Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers
2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Tumor Marker Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...

2017 Europe Immunodiagnostics Market: Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

2017 Europe Immunodiagnostics Market: Over 100 Special Chemistry, Abused Drugs, Endocrine, Immunoprotein, TDM, Tumor MarkerTests--Supplier Shares, Competitive Strategies, Opportunities

  • $ 37500
  • Industry report
  • February 2017
  • by Venture Planning Group

This new 31-country report from VPGMarketResearch.com is available by country, market segment, section, or individual test. This report provides a granular strategic analysis of over 100 clinical chemistry, ...


Download Unlimited Documents from Trusted Public Sources

Hormone and Therapy Market in Pakistan and the US

  • May 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Antipsychotic Market and Psychotic Disorder Statistics in Europe

  • May 2017
    2 pages
  • Antipsychotic  

    Therapy  

    Psychotic Disor...  

  • Europe  

    World  

    Hungary  

View report >

Pharmaceutical Markets in the US

  • May 2017
    8 pages
  • Pharmaceutical  

  • United States  

View report >

Opioid Market

3 days ago

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.